.Attribute Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of individuals with HER2+ innovative breast cancer cells and also active or dependable mind metastases presented constant intracranial task and also wide spread effectiveness of T-DXd.